Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) posted its earnings results on Thursday. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.08), Zacks reports.
Palvella Therapeutics Stock Up 2.6%
Shares of PVLA stock traded up $1.20 on Friday, reaching $47.30. The stock had a trading volume of 190,653 shares, compared to its average volume of 178,101. The firm's 50-day moving average is $30.51 and its two-hundred day moving average is $25.33. The firm has a market capitalization of $523.14 million, a price-to-earnings ratio of -3.91 and a beta of -0.01. Palvella Therapeutics has a 12 month low of $11.17 and a 12 month high of $47.97.
Institutional Investors Weigh In On Palvella Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in Palvella Therapeutics in the 2nd quarter valued at about $104,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter worth approximately $85,000. Marshall Wace LLP boosted its position in shares of Palvella Therapeutics by 61.7% during the 2nd quarter. Marshall Wace LLP now owns 49,077 shares of the company's stock worth $1,106,000 after acquiring an additional 18,732 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter worth approximately $110,000. Finally, Rhumbline Advisers bought a new position in Palvella Therapeutics in the 2nd quarter valued at approximately $224,000. 40.11% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms recently weighed in on PVLA. Canaccord Genuity Group reduced their target price on shares of Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Truist Financial began coverage on shares of Palvella Therapeutics in a research note on Monday, July 21st. They set a "buy" rating and a $56.00 price target for the company. Lifesci Capital initiated coverage on shares of Palvella Therapeutics in a report on Monday, August 4th. They set an "outperform" rating and a $90.00 price objective for the company. HC Wainwright set a $75.00 price target on shares of Palvella Therapeutics and gave the company a "buy" rating in a report on Friday. Finally, Chardan Capital lifted their target price on shares of Palvella Therapeutics from $50.00 to $60.00 and gave the stock a "buy" rating in a report on Friday. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $57.10.
View Our Latest Report on Palvella Therapeutics
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access